WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010030317) THERAPEUTIC DOSING OF A NEUREGULIN OR A SUBSEQUENCE THEREOF FOR TREATMENT OR PROPHYLAXIS OF HEART FAILURE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/030317    International Application No.:    PCT/US2009/004130
Publication Date: 18.03.2010 International Filing Date: 17.07.2009
IPC:
A61K 38/18 (2006.01), A61P 9/00 (2006.01)
Applicants: ACORDA THERAPEUTICS, INC. [US/US]; 15 Skyline Drive Hawthorne, NY 10532 (US) (For All Designated States Except US).
CAGGIANO, Anthony [US/US]; (US) (For US Only).
GANGULY, Anindita [US/US]; (US) (For US Only).
IACI, Jennifer [US/US]; (US) (For US Only).
PARRY, Tom [US/US]; (US) (For US Only)
Inventors: CAGGIANO, Anthony; (US).
GANGULY, Anindita; (US).
IACI, Jennifer; (US).
PARRY, Tom; (US)
Agent: LANDRUM, Charles, P.; Fulbright & Jaworski L.L.P. 600 Congress Avenue Suite 2400 Austing, TX 78701 (US)
Priority Data:
61/135,171 17.07.2008 US
Title (EN) THERAPEUTIC DOSING OF A NEUREGULIN OR A SUBSEQUENCE THEREOF FOR TREATMENT OR PROPHYLAXIS OF HEART FAILURE
(FR) POSOLOGIE THÉRAPEUTIQUE D'UNE NEURÉGULINE OU DE SA SOUS-SÉQUENCE POUR LE TRAITEMENT OU LA PROPHYLAXIE DE L'INSUFFISANCE CARDIAQUE
Abstract: front page image
(EN)The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
(FR)La présente invention concerne le traitement de l'insuffisance cardiaque chez un mammifère. En conséquence, l'invention concerne l'établissement d'un régime posologique, les bénéfices thérapeutiques conférés par l'administration d'une neuréguline telle que le facteur de croissance gliale 2 (GGF2) ou de sa sous-séquence étant conservés et/ou augmentés, tout en réduisant au minimum de façon concomitante tout effet secondaire.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)